DEA Proposes Removal of 6-beta-Naltrexol From Control

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Scheduling Actions

DEA Proposes Removal of 6-beta-Naltrexol From Control

Ken Baumgartner

August 25, 2019 at 13:31:13 ET

The Drug Enforcement Administration is proposing to remove 6-beta-naltrexol from all Controlled Substances Act controls (84 Fed. Reg. 43530, Aug. 21, 2019). The drug, a major metabolite of naltrexone, is a reversible opioid receptor antagonist presently listed in Schedule II for possible use in the treatment of opioid addiction and overdose. Comments on the DEA proposal are due by ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

DEA Proposes Removal of 6-beta-Naltrexol From Control

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT